Noteworthy Path clear for acellular pertussis vaccines

Positive results in two large trials of several acellular pertussis vaccines have validated the technology, and is likely to result in rapid approval of the new vaccines to replace the currently marketed whole killed vaccines.

The National Institute of Allergy and Infectious Diseases (NIAID) announced results of Phase III trials of acellular pertussis vaccines in Italy and Sweden, showing increased efficacy in protecting infants and decreased side effects, compared to both whole-cell DTP (diphtheria-tetanus-pertussis) vaccines and DT vaccines. The institute emphasized that it will work closely with the FDA to speed approvals for the vaccines.